Matrix metalloproteinase-2 (MMP-2) gene polymorphism and cardiovascular comorbidity in type 2 diabetes patients

Journal of Diabetes and its Complications

Volumn 29, Issue 6, 2015, Pages 829-833

  Buraczynska, Monika ^a   Dragan, Michal ^a   Buraczynska, Kinga ^a   Orlowska Kowalik, Grazyna ^a   Ksiazek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

C( 1306)T polymorphism; Cardiovascular disease; MMP 2; Risk allele; Type 2 diabetes

Indexed keywords

GELATINASE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; ENZYME LOCALIZATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION MAPPING; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84942817340     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.05.004     Document Type: Article

References (33)

1. Alp, E., Meneval, S., Tulmac, S., Tulmac, M., Yilmaz, A., Yalcin, R., Cengel, A., et al. (2011). The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genetic Testing and Molecular Biomarkers, 15, 193-202.
2. Bauters, C., Lumblin, N., Ennezat, P. V., Mycinski, C., Tricot, O, Nugue, O, et al. (2007). A prospective evaluation of left ventricular remodeling after inaugural anterior myocardial infarction as a function of gene polymorphisms in the renin-angiotensin-aldosterone, adrenergic and metalloproteinase systems. American Heart Journal, 153, 641-648.
3. Beckman, J. A., Creager, M. A., & Libby, P. (2002). Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA: the journal of the American Medical Association, 287, 2570-2581.
4. Beranek, M., Kolar, P., Tschoplova, S., Kankova, K., & Vasku, A. (2008). Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Molecular Vision, 14, 1114-1121.
5. Brownlee, M. (2005). The pathology of diabetic complications: A unifying mechanism. Diabetes, 54, 1615-1625.
6. Chen, Q., Jin, M., Yang, F., Zhu, J., Xiao, Q., & Zhang, L. (2013). Matrix metalloproteinases: Inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators of Inflammation, http://dx.doi.org/10.1155/2013/928315.
7. Delgado-Enciso, I., Gonzalez-Hernandez, N., Baltazar-Rodriguez, L. M., Millan-Guerrero, R., Newton-Sanchez, O., Bayardo-Noriega, A., et al. (2009). Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. Journal of Genetics, 88, 249-252.
8. Gai, X., Zhang, Z., Liang, Y., Chen, Z., Yang, X., Hou, J., et al. (2010). MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clinica Chimica Acta, 411, 719-724.
9. Galis, Z. S., & Khatri, J. J. (2002). Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad and the ugly. Circulation Research, 90, 251-262.
10. Gonzalez-Hernandez, N. A., Millan-Guerrero, R. O., & Ceja-Espiritu, G. (2008). A polymorphism in the matrix metalloproteinase-2 (MMP-2 -1306 T N C) gene promoter is associated with high risk of ischemic stroke in hypertensive patients. Genes & Genomics, 30, 533-540.
11. Hlatky, M. A., Ashley, E., Quertermous, D. B., Boothroyd, D. B., Ridker, P., Southwick, A., et al. (2007). Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. American Heart Journal, 154, 1043-1051.
12. Huhtala, P., Chow, L. T., & Trygvvason, K. (1990). Structure of the human type IV collagenase gene. Journal of Biological Chemistry, 265, 11077-11082.
13. Kai, H., Ikeda, H., Yasukawa, H., Kai, M., Seki, Y., Kuwahara, F., et al. (1998). Peripheral blood levels of matrix metalloproteinases-2 and-9 are elevated in patients with acute coronary syndromes. Journal of American College of Cardiology, 32, 368-372.
14. Katakami, N., Takahara, M., Kaneto, H., Shimizu, I., Ohno, K., Ishibashi, F., et al. (2010). Accumulation of gene polymorphisms related to plaque disruption and thrombosis is associated with cerebral infarction in subjects with type 2 diabetes. Diabetes Care, 33, 390-395.
15. Manso,H., Krug, T., Sobral, J., Albergaria, I.,Gaspar, G., Ferro, J. M., et al. (2010). Variants of the matrix metalloproteinase-2 but not the matrix metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Medical Genetics, 11, 40-48.
16. Nie, S. W., Wang, S. F., & Tang, Z. C. (2014). Correlations between MMP-2/MMP-9 promoter polymorphisms and ischemic stroke. International Journal of Clinical and Experimental Medicine, 7, 400-404.
17. Noji, Y., Kajinami, K., & Kawashiri, M. A. (2001). Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clinical Chemistry and Laboratory Medicine, 39, 380-384.
18. Olejniczak, I., Fendler, W., Borowiec, M., Mlynarski, W., & Pietruszewska, W. (2012). Polymorphism of metalloproteinases of MMP-1 and MMP-2 in risk of laryngeal cancer. Otolaryngologia Polska, 66, 30-35.
19. Pasterkamp, G., Schoneveld, A. H., & Hijnen, D. J. (2000). Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases-1,-2 and-9 in the human coronary artery. Atherosclerosis, 150, 245-253.
20. Perez-Hernandez, N., Vargas-Alarcon, G., Martinez-Rodriguez, N., Martinez-Rios, R. A., Pena-Duque, M. A, de la Pena-Diaz, A., et al. (2012). The matrix metalloproteinase-2 -1575 gene polymorphism is associated with the risk of developing myocardial infarction in Mexican patients. Journal of Atherosclerosis and Thrombosis, 19, 718-727.
21. Powell, J. T. (2006). Genes predisposing to rapid aneurysm growth. Annals of the New York Academy of Sciences, 1085, 236-241.
22. Price, S. J., Greaves, D. R., & Watkins, H. (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: Role of Sp1 in allele-specific transcriptional regulation. Journal of Biological Chemistry, 276, 7549-7558.
23. Purcell, S., Cherny, S. S., & Sham, P. C. (2003). Genetic power calculator design of linkage and association genetic mapping studies of complex traits. Bioinformatics, 19, 149-150.
24. Siefert, S. A., & Sarkar, R. (2012). Matrix metalloproteinases: Inflammatory regulators in vascular physiology and diseases. Vascular, 20, 210-216.
25. Taylor, J. Y., Kraja, A. T., de Las Fuentes, L., Grimes Stanfill, A., Clark, A., Cashion, A., et al. (2013). An overview of the genomics of metabolic syndrome. Journal of Nursing Scholarship, 45, 52-59.
26. Vasku, A., Goldbergova, M., Izakovicova Holla, L., Siskova, L., Groch, L., Beranek, M., et al. (2004). A haplotype constituted of four MMP-2 promoter polymorphisms (-1575 G/A, -1306 C/T,-790 T/G and-735 C/T) is associated with coronary triple-vessel disease. Matrix Biology, 22, 585-591.
27. Villeneuve, L. M., Reddy, M. A., & Natarajan, R. (2011). Epigenetics: Deciphering the role in diabetes and its chronic complications. Clinical and Experimental Pharmacology and Physiology, 38, 401-409.
28. Visse, R., & Nagase, H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function and biochemistry. Circulation Research, 92, 827-839.
29. Winer, N., & Sowers, J. R. (2004). Epidemiology of diabetes. Journal of Clinical Pharmacology, 44, 397-405.
30. Yabluchanskiy, A., Ma, Y., Padmanabhan Iyer, R., Hall, M. E., & Lindsey, M. L. (2013). Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology, 28, 391-403.
31. Yang, J., Fan, X. H., Guan, Y. Q., Li, Y., Sun, W., Yang, Y-Z, et al. (2010). MMP-2 gene polymorphisms in type 2 diabetesmellitus diabetic retinopathy. International Journal of Ophthalmology, 3, 137-140.
32. Ye, S. (2000). Polymorphism in matrix metalloproteinase gene promoters: Implication in regulation of gene expression and susceptibility of various diseases. Matrix Biology, 19, 623-629.
33. Zhang, B., Ye, S., Herrmann, S. M., Eriksson, P, de Maat, M., Evans, A., et al. (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99, 1788-1794.